Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered microscope could diagnose skin cancer in minutes

NCT ID NCT07682831

Diagnosis Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Aug 20, 2026 · Updated 3 times

Summary

This study tests whether a machine learning model can accurately diagnose two common types of skin cancer—basal cell carcinoma and squamous cell carcinoma—by analyzing images from a special microscope (two-photon microscopy) that scans skin biopsy samples. The goal is to see if this technology can provide a fast, point-of-care diagnosis that matches the results of standard lab analysis. The study involves 92 adults who are having a skin biopsy for suspected non-melanoma skin cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two-photon microscopy imaging device
What this could lead to
If successful, this approach could allow doctors to diagnose common skin cancers like basal cell and squamous cell carcinoma quickly and accurately during a clinic visit, without waiting for lab results.
What could go wrong
This is an early-stage study testing a new imaging and AI method. The machine learning model may not yet match the accuracy of standard pathology, and the technology may not be practical for widespread clinic use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 92 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Punch, excisional or shave biopsy specimen Exclusion Criteria: * Biopsy indication includes melanoma or dysplastic/atypical nevus * Excision thickness of less than 1 mm * Excision longest dimension less than 2 mm * Excision performed as multiple pieces in a single specimen container

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Basal cell carcinoma of skin are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma skin squamous cell carcinoma squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal cell carcinoma of skin Squamous cell carcinoma (skin)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rochester Dermatologic Surgery

    RECRUITING

    Victor, New York, 14654, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.